Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -.--% | -2.11% | +17.72% |
08/04 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
14/03 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Number of employees: 91
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 80 | 100.0 % | 85 | 100.0 % | +6.38% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
62.3
%
| 48 | 60.2 % | 53 | 62.3 % | +10.03% |
United States
29.3
%
| 25 | 31.8 % | 25 | 29.3 % | -2.12% |
Rest of World
8.4
%
| 6 | 7.9 % | 7 | 8.4 % | +12.78% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 01/23/01 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
Ryan Lennox
CMP | Compliance Officer | 43 | 07/18/07 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/14/01 |
Brian Walsh
PRN | Corporate Officer/Principal | - | 01/23/01 |
Patricia Perry
HRO | Human Resources Officer | 48 | 01/19/01 |
David Spence
AUD | Comptroller/Controller/Auditor | 56 | 01/18/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 18/21/18 |
Laura Brege
BRD | Director/Board Member | 66 | 21/19/21 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
Craig Millian
CEO | Chief Executive Officer | 56 | 01/23/01 |
Rodney Hill
BRD | Director/Board Member | 56 | 12/18/12 |
Norma Beauchamp
BRD | Director/Board Member | 62 | 01/21/01 |
Kyle Dempsey
BRD | Director/Board Member | 35 | 29/22/29 |
Christian Roy
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,886,247 | 31,730,547 ( 99.51 %) | 0 | 99.51 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 108M | |
+14.89% | 70.59B | |
+2.07% | 25.06B | |
+7.11% | 8.2B | |
-20.55% | 7.96B | |
-2.98% | 7.92B | |
+3.91% | 4.71B | |
+17.12% | 4.32B | |
-1.24% | 4.01B | |
-3.44% | 3.82B |
- Stock Market
- Equities
- HLS Stock
- Company HLS Therapeutics Inc.